Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1864 results
April 2020
-
Featured News
World Chagas Disease Day 2020
Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach.
-
Featured News
Novartis COVID-19 Response Fund provides support to healthcare workers and communities
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
-
Statement
Novartis announces first European donation of hydroxychloroquine to Switzerland
-
Press Release
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus… -
Key Release
Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to…
March 2020
-
Press Release
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified… -
Statement
Novartis announces further steps to protect and support its associates during the COVID-19 Pandemic
-
Story Discovery
Visualizing molecular glues
Molecular glues are a new type of medicine inspired by nature’s matchmakers.
-
Key Release
Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data1 If approved, Cosentyx would… -
Key Release
AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and… -
Story Patient Perspectives
Caring for someone with heart failure
Caring for someone with heart failure can be both demanding and rewarding. Learn about the impact of being a carer and the support that carers need.
-
Press Release
Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
Collaboration to address product development and scale up challenges posed by current pandemic Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an…